IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Schaper Benz & Wise Investment Counsel Inc. WI

Schaper Benz & Wise Investment Counsel Inc. WI boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 44,502 shares of the company’s stock after buying an additional 3,400 shares during the quarter. IDEXX Laboratories accounts for 1.5% of Schaper Benz & Wise Investment Counsel Inc. WI’s holdings, making the stock its 24th largest position. Schaper Benz & Wise Investment Counsel Inc. WI’s holdings in IDEXX Laboratories were worth $18,399,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Insight Wealth Strategies LLC grew its position in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after buying an additional 7,041 shares during the last quarter. Larson Financial Group LLC grew its position in IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after buying an additional 2,241 shares during the last quarter. Quest Partners LLC grew its position in IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after buying an additional 2,801 shares during the last quarter. Crystal Rock Capital Management grew its position in IDEXX Laboratories by 90.0% in the third quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after buying an additional 4,265 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in IDEXX Laboratories by 3.4% in the third quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock worth $72,059,000 after buying an additional 4,696 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Up 0.3 %

IDEXX Laboratories stock opened at $430.12 on Friday. The firm has a market cap of $34.98 billion, a price-to-earnings ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $562.25. The firm has a fifty day moving average price of $437.37 and a two-hundred day moving average price of $449.41.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research analyst reports. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Piper Sandler lifted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.